Search Result

Results for "

kras+g12c+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (9) Caspase (3) CDK (1) Drug Derivative (1) Drug Intermediate (1) Drug Isomer (3) ERK (6) Fluorescent Dye (1) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (1) Mitochondrial Metabolism (1) mTOR (1) p38 MAPK (3) PARP (1) PERK (7) PI3K (1) PROTACs (3) Ras (112) Reactive Oxygen Species (ROS) (2) SOS1 (2) TNF Receptor (2)
By Research Areas:	Cancer (119) Inflammation/Immunology (2)
Click Chemistry:	Alkynes (6)

119

Inhibitors & Agonists

Screening Libraries

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-152848

Fulzerasib IBI351; GFH925	Ras	Cancer
Fulzerasib (GFH925) is an irreversible *KRAS* G12C inhibitor, has a synergistic anti-cancer effect with cetuximab (HY-P9905). .

HY-143589

Glecirasib JAB-21822; KRAS G12C inhibitor 36	Ras	Cancer
Glecirasib (Compound 1-2; JAB-21822) is an orally active and potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. Glecirasib has the potential for the research of KRAS G12C-mediated cancer .

HY-132980

Olomorasib 2 Publications Verification KRAS G12C inhibitor 19	Ras	Cancer
Olomorasib is a potent inhibitor of KRAS G12C. Olomorasib significantly inhibits tumor growth (extracted from patent WO2021118877A1) .

HY-162431

Calderasib MK-1084	Ras	Cancer
Calderasib (MK-1084) is a selective *KRAS G12C* inhibitor. Calderasib exhibits anticancer activity and can be used either alone or in combination with Pembrolizumab (HY-P9902) for cancer research .

HY-148098

*Pan KRas-IN-1* 1 Publications Verification	Ras	Cancer
Pan KRas-IN-1 is a pan KRas inhibitor, can be used for agent resistance in cancer developed with KRas G12C inhibitors .

HY-W016889

CFL-137	Ras	Cancer
CFL-137 is a potent *KRas ^G12C* inhibitor. CFL-137 shows an antiproliferative effect. CFL-137 shows anticancer activity. CFL-137 has the potential for the research of lung cancer .

HY-164315

KRAS G12C inhibitor 67	Ras PERK	Cancer
KRAS G12C inhibitor 67 (Example 35) is an orally active *KRAS G12C* inhibitor. KRAS G12C inhibitor 67 inhibits pERK and active KRas. KRAS G12C inhibitor 67 selectively inhibits the growth of various KRAS G12C mutant tumor cell lines. KRAS G12C inhibitor 67 exhibits anticancer activity against esophageal cancer, bladder cancer, colorectal cancer, lung cancer, and pancreatic cancer .

HY-U00418

ARS-1620 Maximum Cited Publications 12 Publications Verification	Ras	Cancer
ARS-1620 is an atropisomeric selective *KRAS ^G12C* inhibitor with desirable pharmacokinetics.

HY-139612

Opnurasib 5+ Cited Publications JDQ-443; NVP-JDQ443	Ras PERK	Inflammation/Immunology Cancer
Opnurasib (JDQ-443) (NVP-JDQ443) is an orally active, potent, selective, and covalent *KRAS G12C* inhibitor. Opnurasib shows antitumor activity .

HY-114436

MRTX-1257 5 Publications Verification	Ras	Cancer
MRTX-1257 is a selective, irreversible, covalent and orally active *KRAS G12C* inhibitor, with an IC₅₀ of 900 pM for KRAS dependent ERK phosphorylation in H358 cells .

HY-154959

AZD4747	Ras	Cancer
AZD4747 is a selective, blood-brain barrier-permeable mutant GTPase *KRAS ^G12C* inhibitor. AZD4747 has the potential to study cancer .

HY-19706

ARS-853 5 Publications Verification	Ras Apoptosis	Cancer
ARS-853 is a cell-active, selective, covalent *KRAS G12C* inhibitor with an IC₅₀ of 2.5 μM. ARS-853 inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein and preventing activation .

HY-148261

KRAS G12C inhibitor 56	Ras	Cancer
KRAS G12C inhibitor 56 (compound IC-6) is a potent SOS1 inhibitor with an IC₅₀ of 1.6 nM. KRAS G12C inhibitor 56 can be used in cancer research .

HY-134654

MRTX849 analog 24	Fluorescent Dye	Cancer
MRTX849 analog 24 is an alkyne-containing click probe analogue of KRAS G12C inhibitor MRTX849, which is used to research MRTX849 function .

HY-153262

(7R)-Elisrasib (7R)-D3S-001	Ras	Cancer
KRASG12C IN-2 (compound 17) is an orally active *KRAS ^G12C* inhibitor. KRASG12C IN-2 inhibits tumor growth in mice .

HY-164493

KRASG12C IN-13	Ras	Cancer
KRASG12C IN-13 (LY3499446) is a potent *KRAS G12C* inhibitor. KRASG12C IN-13 is promising for research of advanced solid tumors including non-small cell lung cancer and colorectal cancer .

HY-139612A

(S)-Opnurasib (S)-JDQ-443; (S)-NVP-JDQ443	Drug Isomer Ras PERK	Inflammation/Immunology Cancer
(S)-Opnurasib ((S)-JDQ-443; (S)-NVP-JDQ443) is an isomer of Opnurasib (HY-139612). Opnurasib is an orally active, potent, selective, and covalent *KRAS G12C* inhibitor (extracted from patent WO2021120890A1). Opnurasib shows antitumor activity .

HY-U00416

ARS-1323	Ras	Cancer
ARS-1323 is a *KRAS G12C* inhibitor. ARS-1323 specifically binds to the cysteine residue on the mutant K-Ras protein, locks it in the GDP-bound conformation, thereby blocking K-Ras activation and downstream signaling pathways. ARS-1323 can be used to investigate the signal transduction mechanisms and growth characteristics of tumor cells driven by K-Ras G12C .

HY-125872

KRAS G12C inhibitor 14	Ras	Cancer
KRas G12C inhibitor 14 (Compound 17) is a potent *KRAS G12C* inhibitor (IC₅₀ = 18 nM).

HY-132966

ASP2453 1 Publications Verification	Ras ERK	Cancer
ASP2453 is a potent, selective and orally active *KRAS G12C* inhibitor. ASP2453 inhibits the Son of Sevenless (SOS)-mediated interaction between *KRAS G12C* and Raf with an IC₅₀** value of 40 nM.

HY-143592

KRAS G12C inhibitor 39	Ras	Cancer
KRAS G12C inhibitor 39 is a potent inhibitor of KRAS G12C. KRas is a highly attractable target of the pharmaceutical industry for cancer research. KRAS G12C inhibitor 39 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2019099524A1, compound 494) .

HY-135865

KRAS inhibitor-7	Ras	Cancer
KRAS inhibitor-7 is a potent *KRAS G12C* inhibitor, extracted from patent WO2017087528A1, compound B .

HY-W041315

CFL-120	Ras	Cancer
CFL-120 is a potent *KRas ^G12C* inhibitor. CFL-120 shows an antiproliferative effect. CFL-120 shows anticancer activity. CFL-120 has the potential for the research of lung cancer .

HY-142460

KRAS G12C inhibitor 28	Ras	Cancer
KRAS G12C inhibitor 28 is a *KRAS G12C* inhibitor with an IC₅₀ of 57 nM. KRAS G12C inhibitor 28 has antitumor effects (WO2021113595A1; Example 1) .

HY-147636

KRAS G12C inhibitor 55	Ras	Cancer
KRAS G12C inhibitor 55 (Compound 1) is a *KRAS G12C* inhibitor .

HY-142946

KRAS G12C inhibitor 44	Ras	Cancer
KRAS G12C inhibitor 44 (compound 54) is a potent and orally active *KRAS G12C* inhibitor. KRAS G12C inhibitor 44 shows anti-proliferation activities with IC₅₀s of 0.016, 0.028 µM in MIA PaCA-2, H358 cells, respectively. KRAS G12C inhibitor 44 shows antitumor effects in vivo .

HY-125873

KRAS G12C inhibitor 15	Ras	Cancer
KRAS G12C inhibitor 15 is a potent *KRAS G12C* inhibitor extracted from patent WO2019110751A1, compound 22, has an IC₅₀ of 5 nM .

HY-112494

KRas G12C inhibitor 4	Ras	Cancer
KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.

HY-172237

Sosimerasib	Ras	Cancer
Sosimerasib is an orally active *KRAS ^G12C* inhibitor. Sosimerasib can be used in research related to non-small cell lung cancer .

HY-154959A

(9R,12aR)-AZD4747	Ras	Cancer
(9R,12aR)-AZD4747 is a diastereomer of AZD4747 (HY-154959). AZD4747 is a selective mutant GTPase KRAS ^G12C inhibitor with blood-brain barrier permeability. AZD4747 has the potential to study cancer .

HY-114436S

MRTX-1257-d6	Isotope-Labeled Compounds	Cancer
MRTX-1257-d₆ is the deuterium labeled MRTX-1257 (HY-114436). MRTX-1257 is a selective, irreversible, covalent and orally active *KRAS G12C* inhibitor, with an IC₅₀ of 900 pM for KRAS dependent ERK phosphorylation in H358 cells .

HY-163720

KRAS G12C inhibitor 63	Ras Apoptosis	Cancer
KRAS G12C inhibitor 63 (K45) is a *KRAS G12C* inhibitor. KRAS G12C inhibitor 63 can induce Apoptosis. KRAS G12C inhibitor 63 has antitumor activity .

HY-159611

KRAS G12C inhibitor 68	Ras	Cancer
KRAS G12C inhibitor 68 (compound I-063) is a *KRAS G12C* inhibitor with an IC₅₀ of 7 nM. KRAS G12C inhibitor 68 has anti-tumor activity .

HY-147633

KRAS G12C inhibitor 52	Ras	Cancer
KRAS G12C inhibitor 52 (Compound 7) is a *KRAS G12C* inhibitor .

HY-147632

KRAS G12C inhibitor 51	Ras	Cancer
KRAS G12C inhibitor 51 (example 1) is a *KRAS G12C* inhibitor .

HY-147635

KRAS G12C inhibitor 54	Ras	Cancer
KRAS G12C inhibitor 54 (Compound 1) is a *KRAS G12C* inhibitor .

HY-147634

KRAS G12C inhibitor 53	Ras	Cancer
KRAS G12C inhibitor 53 (Compound 1) is a *KRAS G12C* inhibitor .

HY-145020

KRAS G12C inhibitor 23	Ras	Cancer
KRAS G12C inhibitor 23 is a *KRAS G12C* inhibitor. KRAS G12C inhibitor 23 inhibits H358 cells with an IC₅₀ of 491 nM (WO2021218939A1, compound 1) .

HY-153461

KRAS G12C inhibitor 58	Ras	Cancer
KRAS G12C inhibitor 58 is a *KRAS G12C* inhibitor, used in cancer research .

HY-142947

KRAS G12C inhibitor 45	Ras	Cancer
KRAS G12C inhibitor 45 (compound 78) is a potent *KRAS G12C* inhibitor .

HY-142478

KRAS G12C inhibitor 29	Ras	Cancer
KRAS G12C inhibitor 29 is a *KRAS G12C* inhibitor extracted from patent WO2021252339A1, compound 3. KRAS G12C inhibitor 29 can be used for the research of cancer .

HY-142485

KRAS G12C inhibitor 31	Ras	Cancer
KRAS G12C inhibitor 31 is a *KRAS G12C* inhibitor extracted from patent WO2021252339A1, compound 1. KRAS G12C inhibitor 31 can be used for the research of cancer .

HY-142481

KRAS G12C inhibitor 30	Ras	Cancer
KRAS G12C inhibitor 30 is a *KRAS G12C* inhibitor extracted from patent WO2021252339A1, compound 2. KRAS G12C inhibitor 30 can be used for the research of cancer .

HY-142490

KRAS G12C inhibitor 33	Ras	Cancer
KRAS G12C inhibitor 33 is a *KRAS G12C* inhibitor extracted from patent WO2021244603A1, compound 1. KRAS G12C inhibitor 33 can be used for the research of cancer .

HY-142511

KRAS G12C inhibitor 34	Ras	Cancer
KRAS G12C inhibitor 34 is a *KRAS G12C* inhibitor extracted from patent WO2021239058A1, compound Z1. KRAS G12C inhibitor 34 can be used for the research of cancer .

HY-153944

KRAS G12C inhibitor 60	Ras	Cancer
KRAS G12C inhibitor 60 (compound 23) is a *Kras-G12C* inhibitor. KRAS G12C inhibitor 60 can be used for the research of lung cancer, colorectal cancer, pancreatic cancer .

HY-142948

KRAS G12C inhibitor 46	Ras	Cancer
KRAS G12C inhibitor 46 (compound WX003) is a potent *KRAS G12C* inhibitor .

HY-142458

KRAS G12C inhibitor 27	Ras	Cancer
KRAS G12C inhibitor 27 is a *KRAS G12C* inhibitor with antitumor effects (WO2021109737) .

HY-142457

KRAS G12C inhibitor 26	Ras	Cancer
KRAS G12C inhibitor 26 is a *KRAS G12C* inhibitor with antitumor effects (WO2021109737) .

HY-147631

KRAS G12C inhibitor 50	Ras	Cancer
KRAS G12C inhibitor 50 (Example 4) is a *KRAS G12C* inhibitor with an IC₅₀ of 46.7 nM .

Cat. No.	Product Name

HY-L260

KRAS Targeted Compound Library

0 compounds

KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is one of the most important oncogenic driver genes in oncology, with high mutation frequencies in pancreatic cancer, non‑small cell lung cancer, and colorectal cancer. For a long time, KRAS was considered "undruggable" due to the lack of suitable small‑molecule binding pockets on its protein surface. In recent years, with the discovery of the switch‑II pocket and the successful approval of KRAS G12C inhibitors, KRAS‑targeted research has achieved groundbreaking progress, which has also spurred a wave of development targeting non‑G12C mutants such as G12D and G12V, as well as upstream and downstream regulatory factors including SOS1 and SHP2.

MCE KRAS Targeted Compound Library contains 0 small‑molecule compounds targeting the KRAS, serving as high‑quality research tools for mechanistic studies of KRAS‑mutant tumors, combination therapy development, resistance mechanism exploration, and high‑throughput drug screening, thereby providing robust support for KRAS‑targeted drug discovery.

Cat. No.	Product Name	Chemical Structure

HY-176785S

MCB-294

MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with K_ds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC₅₀s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRAS ^G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer .

HY-114436S

MRTX-1257-d6
MRTX-1257-d₆ is the deuterium labeled MRTX-1257 (HY-114436). MRTX-1257 is a selective, irreversible, covalent and orally active *KRAS G12C* inhibitor, with an IC₅₀ of 900 pM for KRAS dependent ERK phosphorylation in H358 cells .

Cat. No.	Product Name		Classification

HY-128522

ARS-1323-alkyne		Alkynes
ARS-1323-alkyne is a covalent inhibitor probe that covalently binds to the Switch-II pocket (S-IIP) of the KRAS G12C mutant protein. ARS-1323-alkyne visualizes the covalent modification of KRAS G12C and quantitatively measures the binding efficiency of the inhibitor to the target. ARS-1323-alkyne can be used to validate the target occupancy of KRAS G12C inhibitors and the synergistic mechanism of combination therapy .

HY-176786

MCB-36		Alkynes
MCB-36 is a VHL-recruiting pan-KRAS PROTAC degrader without affecting KRAS transcription. MCB-36 exhibits minimal effects on HRAS and NRAS protein levels. MCB-36 binds to the GDP-loaded state of G12D, G12C, G12V, and wild-type KRAS with high affinities K_d ≈ 1 pM). MCB-36 decreases p-ERK levels, leading to cell apoptosis. MCB-36 effectively suppress KRAS ^G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-36 can be used for the study of colorectal cancer and lung cancer (Pink: Target protein ligand; Blue: E3 ligand (HY-112078); Black: Linker (HY-W091879)) .

HY-176785S

MCB-294		Alkynes
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with K_ds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC₅₀s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRAS ^G12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer .

HY-134654

MRTX849 analog 24		Alkynes
MRTX849 analog 24 is an alkyne-containing click probe analogue of KRAS G12C inhibitor MRTX849, which is used to research MRTX849 function .

HY-179403

KRASG12C IN-17		Alkynes
KRASG12C IN-17 is an orally active covalent KRAS ^G12C inhibitor, showing strong inhibitory activity in KRAS ^G12C-mutant cancer cells (NCI-H23 IC₅₀ = 0.7 nM; NCI-H358 IC₅₀ = 0.5 nM). KRASG12C IN-17 covalently and irreversibly binds to KRAS ^G12C with > 96% modification efficiency in both GDP-bound and GMPPNP-bound conformations. KRASG12C IN-17 can be used for studies of KRAS-driven cancers, including colorectal cancer .

HY-179404

KRASG12C IN-18		Alkynes
KRASG12C IN-18 is an orally active covalent KRAS ^G12C inhibitor that achieves complete covalent engagement of KRAS ^G12C in both GDP- and GMPPNP-bound states and displays strong antiproliferative activity against KRAS ^G12C and resistance-associated variants, including KRAS ^G12C/R68S, with low-nanomolar IC₅₀ values. KRASG12C IN-18 exhibits marked in vivo efficacy in KRAS ^G12C-driven solid tumor and KRAS ^G12C/R68S xenograft models and can be used for colorectal cancer research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: